30 closest matches · ranked by relevance
Venous Thromboembolism
Primary: Number of Participants With Postoperative VTE Within 48 Hours After Surgery — 5; 3 participants — p=0.72
Venous Thromboembolism (VTE) · Deep Vein Thrombosis (DVT) · Pulmonary Embolism (PE)
Primary: Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event — 67; 71 Participants — p=0.0056
Venous Thromboembolism
Primary: Recurrent Venous Thromboembolism — 32; 46 Participants
Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
Primary: 2-Month Cumulative Incidence of VTE — 5.6; 27.2; 7.2 percent probability — p=0.06
Cerebral Vein Thrombosis · Deep Vein Thrombosis · Gonadal Thrombosis
Primary: 6 Month Bleeding Rate — 0; 2.1 percentage of patients
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 1 participants
Pancreatic Cancer · Venous Thromboembolism
Primary: Number of Participants With Venous Thromboembolic Events (VTE) — 2; 9 participants
Neoplasms
Primary: Percentage of Participants With Time to First Occurrence of Primary Efficacy Endpoint (Composite and Components) — 8.79; 5.95; 1.90; 2.14 Percentage of participants…
Upper Extremity Deep Vein Thrombosis · Central Venous Catheter Thrombosis · Cancer
Primary: Primary Feasibility Outcome - Number of Participants Recruited Per Month — 7.5; 2.0 Average enrolment rate/month/site
Cerebral Vein Thrombosis · Deep Vein Thrombosis · Hematopoietic and Lymphoid Cell Neoplasm
Primary: CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk — 9.6; 13.5 proportion of participants — p=0.3117
Acute Deep Vein Thrombosis
Primary: Number of Participants With Resolution of Deep Vein Thrombosis (DVT) of the Leg — 43 Participants
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
Cancer · Venous Thromboembolism · Deep Vein Thrombosis (DVT)
Primary: Cumulative Non-Fatal VTE Recurrence at 6 Months (%) — 6.1; 8.8; 7.5; 4.1 percentage of patients
Vascular Diseases · Embolism and Thrombosis · Phlebitis
Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants
Venous Thrombosis · Neoplasms
Primary: PTS Assessment Completion — 17 Participants
Thromboembolism of Vein VTE in Colorectal Cancer · Thromboembolism of Vein in Pancreatic Cancer · Thromboembolism of Vein in Non-small Cell Lung Cancer
Primary: Percent Change in D-dimer Value — 9.9; -21.9 percent change — p=0.92
Thromboembolism
Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 4.731; 0.986 months
Metastatic Colorectal Cancer
Primary: Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination) — 373.00; 370.00 days — p=0.967
Venous Thromboembolism
Primary: Median Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Level — 125 IU/mL
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Progression-free Survival Rate — 53.2 percentage of participants
Colon Cancer · Colorectal Cancer
Primary: Maximum Tolerated Dose (MTD) of Celebrex in Combination With EPO906 — 9 mg/m2
Colorectal Cancer
Primary: Progression-free Survival (PFS) — 55 Days
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Metastatic Colorectal Cancer
Primary: Progression-free Survival — 8.6; 8.2 Months
Colorectal Cancer · Colorectal Carcinoma · Colorectal Adenocarcinoma
Primary: Number of Participants With Grade 1-5 Adverse Events — 4; 12; 4; 13 Participants
Bone Sarcoma · Femur Fracture · Lymphoma
Primary: Number of Participants With Post-operative Wound Complications — 1; 4; 0; 3 Participants